Pharmaceutical Analysis

Tuesday, October 12 at 10am EDT | 3pm BST | 4pm CEST and 1pm EDT | 12pm CDT | 10am PDT Discover the latest advances in instrumentation and applications for hydrocarbon processing, agrochemicals, and pharmaceuticals.

Thursday, September 30 at 10am EDT | 3pm BST | 4pm CEST and 1pm EDT | 12pm CDT | 10am PDT Discover the latest advances in instrumentation and applications for hydrocarbon processing, agrochemicals, and pharmaceuticals.

This concise yet comprehensive overview of sample preparation for bioanalysis looks at sample preparation fundamentals, best practices, and modern trends—all illustrated with a case study.

This article discusses the development of a series of applications that will allow for the determination of a number of nitrosamines that have been identified by the FDA as genotoxins to monitor, initially showing how to perform a separation of these compounds from the API and then looking at how MS can be applied to the analysis to ensure that the required detection limits can be reached.

This is the first article in a four-part series exploring the quantitative assessment of drugs and their metabolites in biological fluids (such as blood, plasma, and urine) and tissue homogenates using liquid chromatography–mass spectrometry (LC–MS).

We assess recent advances in cleaning verification methods for small-molecule pharmaceuticals, and propose a workflow.

Is there a secret formula to getting hired into a pharmaceutical analytical chemistry group? What skills are prized above all others?

Ion-exchange chromatography (IEX) is a frequently overlooked technique. This novel IEX method uses non-aqueous mobile phases to purify a non-crystalline intermediate after a reductive amination with D-xylose. IEX delivers a step change in strength and purity of the intermediate allowing successful downstream processing.

Drug substance development requires a range of analytical methods to be developed to generate process knowledge and to support in-process and release testing throughout a synthetic sequence. This article describes practical examples of a wide variety of transfer challenges and our remediation strategy.

This Friday morning session honors the 2021 LCGC award winners: Paul Haddad of the University of Tasmania, and the foundation director of the Australian Centre for Research on Separation Science (ACROSS); and Erik L. Regalado, of the pharmaceutical company Merck & Co.

The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.

Incognito leads us through the complex method used to determine related substances for hydroxychloroquine, exploring the practical implementation and critical evaluation of a less than optimum ultrahigh-pressure liquid chromatography (UHPLC) pharmacopeial method.

In the pharmaceutical industry, method validation is essential. But what are the best practices? We review regulatory requirements, validation parameters, methodologies, acceptance criteria, trends, and software tools.

Here we provide an overview of the fundamentals and best practices on the development of stability-indicating HPLC methods for drug substances and products. We explain both traditional and easier modern approaches to developing stability-indicating HPLC methods—including using a universal generic method for new chemical entities—and address regulatory considerations and life cycle management strategies.

Determining product shelf life is a regulatory requirement for pharmaceuticals and many other regulated consumer products. In this comprehensive overview of stability studies and testing, we summarize current regulatory requirements, share industry practices for forced degradation, and explain approaches for reduced testing and data evaluation to expedite stability study timelines.

A fast ultrahigh-pressure liquid chromatography (UHPLC) method, with low solvent consumption, is described for the determination of coenzyme Q10 in a variety of complex formulations. This method exhibits good linearity, reproducibility, accuracy, recovery, and specificity, while resulting in an acceptable limit of detection (LOD) and limit of quantification (LOQ).

This article will discuss the benefits of 2D-LC and multiple application areas in (bio)pharmaceutical analysis, and will highlight the challenges and future outlook.

This article presents possible uses of ion chromatography and related techniques combined with various detection methods for clinical and pharmaceutical analysis of common inorganic and organic anions and cations. An overview of achievements in this area from the past 10 years is presented and the most important trends and development perspectives for ion chromatography are described.

The main objective of this review article is to provide a clear summary of the different methods that can be used to quantify endogenous small molecules. Because of the increased use of mass spectrometry (MS) in the field of bioanalysis, a special focus will be placed on quantification by liquid chromatography (LC)–MS. Practical recommendations to face this bioanalytical challenge, in particular in terms of method validation, will also be provided.

The main objective of this review article is to provide a clear summary of the different methods that can be used to quantify endogenous small molecules. Because of the increased use of mass spectrometry (MS) in the field of bioanalysis, a special focus will be placed on quantification by liquid chromatography (LC)–MS. Practical recommendations to face this bioanalytical challenge, in particular in terms of method validation, will also be provided.

The European Pharmacopoeia (Ph. Eur.) defi nes requirements for the qualitative and quantitative composition of medicines, as well as the tests to be carried out on medicines and on substances and materials used in their production.

This article focuses on ways to accelerate glycan screening data analysis, while keeping high reproducibility.A major focus of the pharmaceutical industry is the production and development of biologics-therapeutics produced via biological means-to provide novel treatments for diseases with unmet clinical needs. A large percentage of biologics under development are proteins, such as monoclonal antibodies (mAbs), fusion proteins, antibody–drug conjugates (ADCs), and enzymes. The structures of these protein drugs are made more complex by post‑translational modifications (PTMs).

For your highly sensitive UHPLC–MS analyses, how can you reduce noise and additional signals to a minimum?

Here we applied our newly developed UHPLC C18 and C30 columns to oligonucleotide analysis.

In this application, a simple method to simultaneously analyze various water-soluble vitamins was developed.

This review article will give a general overview of the liquid chromatographic (LC) and gas chromatographic (GC) methods used by analytical laboratories for the detection and characterization of suspected illegal medicines and health products, including lifesaving drugs (antimicrobials and antimalarials), lifestyle drugs (erectile dysfunction drugs), and biotechnology drugs (doping peptides and skin-tanning peptides). Literature published from 2015 until early 2019 will be surveyed.

LCGC Europe spoke to Yong Liu and Adam Socia from MSD about the cost-saving benefits of implementing green chromatography in the pharmaceutical sector, the importance of analytical method volume intensity (AMVI), and effective practices to reduce solvent consumption and replace harmful solvents, including supercritical fluid chromatography (SFC), fast chromatography, and “cocktail chromatography”.

This review article will give a general overview of the liquid chromatographic (LC) and gas chromatographic (GC) methods used by analytical laboratories for the detection and characterization of suspected illegal medicines and health products, including lifesaving drugs (antimicrobials and antimalarials), lifestyle drugs (erectile dysfunction drugs), and biotechnology drugs (doping peptides and skin-tanning peptides). Literature published from 2015 until early 2019 will be surveyed.

This article reviews the changing role of mass spectrometry (MS) hyphenated to reversed-phase liquid chromatography (LC) and alternative separation techniques in late-stage pharmaceutical development. The impact of the changing portfolios within the pharmaceutical industry is discussed as the industry moves from a traditional small-molecule model to a more diverse portfolio. A new generation of high‑resolution mass spectrometers and ion mobility mass spectrometers operating as orthogonal separation techniques has greatly increased the ability to resolve impurities and increase the level of knowledge gained from a single experiment. The continued impact and innovation of gas chromatographyÐmass spectrometry (GCÐMS) in late-stage development is also discussed.

The evolution of two-dimensional liquid chromatography (2D-LC) instruments along with improved software capabilities has transferred 2D-LC from the hands of experienced researchers to functioning analytical laboratories in the pharmaceutical industry. 2D-LC offers chromatographers novel solutions to problems ranging from analyzing complex samples requiring excessively large peak capacities to separating simple compounds that are difficult to resolve. Recent developments in 2D-LC and 2D-LC–MS have demonstrated the potential of this technique in practice and 2D-LC is set to become an essential tool in the pharmaceutical sector to address problems ranging from coelution, peak purity assessment, simultaneous achiral-chiral analysis, genotoxic impurities, and more.